Keryx raises $33 million, as it moves forward with PHIII testing for Zerenex for hyperphosphataemia
This article was originally published in Scrip
Executive Summary
Keryx Biopharmaceuticals has raised $33 million through the sale of 7,021,277 shares at $4.70 per share in a secondary stock offering on 5 May. The news of the offeringwas marked by a 5% drip in Keryx price over the day, with the market acknowledging around $20 million of the money raised in its valuation change for the company.